ReviewDiabetes therapy : research, treatment and education of diabetes and related disorders2023
A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems.
Review in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07284511 (Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide), which is not on this map. Cited by 54 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel Trial
Who cites it
54 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Stakeholder Perspectives on the Integration of AI in Diabetes Care: Systematic Review of Qualitative Studies.Journal of medical Internet research · 2026Pooled it
- A systematic literature review and meta-analysis of real-world evidence on commercially available automated insulin delivery systems in people with type 1 diabetes.Diabetes, obesity & metabolism · 2026Pooled it
- Automated insulin delivery in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis.Acta diabetologica · 2025Pooled it
- Ultra-rapid lispro or fast-acting aspart compared to standard insulin lispro and aspart using closed-loop insulin therapy: a systematic review and meta-analysis of randomized control trials.Frontiers in endocrinology · 2025Pooled it
- Efficacy of the hybrid closedloop insulin delivery system in children and adolescents with type 1 diabetes: a meta-analysis with trial sequential analysis.Archives of endocrinology and metabolism · 2024Pooled it
- Real-World Evidence of Automated Insulin Delivery System Use.Diabetes technology & therapeutics · 2024Pooled it
- Recommendations for recognizing, risk stratifying, treating, and managing children and adolescents with hypoglycemia.Frontiers in endocrinology · 2024Pooled it
- Extended Use of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 1 Diabetes: 12-Month Extension of a Randomized Controlled Trial.Endocrinology, diabetes & metabolism · 2026Trial
- Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel-group clinical trial sub-study.Diabetes, obesity & metabolism · 2026Trial
- Automated insulin delivery during the first 6 months postpartum (AiDAPT): a prespecified extension study.The lancet. Diabetes & endocrinology · 2025Trial
- Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial.Frontiers in endocrinology · 2025Trial
- Looking Beyond Glycaemic Control: Real-World 12-Month Cardiometabolic and Retinopathy Outcomes Following Omnipod 5 Initiation in People With Type 1 Diabetes.Diabetes, obesity & metabolism · 2026Article
- The Emerging Potential of Diabetes Technology to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Type 1 Diabetes: A Narrative Review.Biomedicines · 2026Review
- Clinical utility of the twiist Automated Insulin Delivery System: first study with twiist.BMJ open diabetes research & care · 2026Article
- The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long-Acting Insulin Analogues for Diabetes Mellitus.Diabetes, obesity & metabolism · 2026Review
- Twelve-Month Real-World Use of an Advanced Hybrid Closed-Loop System Versus Previous Therapy in a Dutch Center For Specialized Type 1 Diabetes Care.Journal of diabetes science and technology · 2026Article
- Challenges and Opportunities for Improving Care for Type 1 Diabetes in Older Adulthood.Diabetes care · 2026Review
- Discordant real-world glycaemic outcomes with Omnipod™ 5 and MiniMed™ 780G in adults with type 1 diabetes: Why validated measures matter.Diabetes, obesity & metabolism · 2026Article
- What is the impact of an advanced hybrid closed-loop system on weight control among people with type 1 diabetes?Diabetes, obesity & metabolism · 2026Article
- Fully closed-loop systems: can people with type 1 diabetes just do it? Insights from open-source systems.Diabetologia · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSeveral different forms of automated insulin delivery systems (AID systems) have recently been developed and are now licensed for type 1 diabetes (T1D). We undertook a systematic review of reported trials and real-world studies for commercial hybrid closed-loop (HCL) systems.
methodsPivotal, phase III and real-world studies using commercial HCL systems that are currently approved for use in type 1 diabetes were reviewed with a devised protocol using the Medline database.
resultsFifty-nine studies were included in the systematic review (19 for 670G; 8 for 780G; 11 for Control-IQ; 14 for CamAPS FX; 4 for Diabeloop; and 3 for Omnipod 5). Twenty were real-world studies, and 39 were trials or sub-analyses. Twenty-three studies, including 17 additional studies, related to psychosocial outcomes and were analysed separately.
conclusionsThese studies highlighted that HCL systems improve time In range (TIR) and arouse minimal concerns around severe hypoglycaemia. HCL systems are an effective and safe option for improving diabetes care. Real-world comparisons between systems and their effects on psychological outcomes require further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.